Tags
knee cartilage
Tags
osteoarthritis treatment
154 results found in 51ms
When cartilage repair is the right choiceWhen cartilage repair is the right choice
Cartilage repair is suited to younger, active patients with isolated damage in otherwise healthy joints where conservative care has not worked. It is mechanistically impossible when underlying bone is worn smooth, degeneration spans multiple compartments, or malalignment and instability persist uncorrected.Cartilage repair is suited to younger, active patients with isolated damage in otherwise healthy joints where conservative care has not worked. It is mechanistically impossible when underlying bone is worn smooth, degeneration spans multiple compartments, or malalignment and instability persist uncorrected.
Can ChondroFiller delay joint replacement?Can ChondroFiller delay joint replacement?
An injectable collagen scaffold called ChondroFiller recruits the patient's own repair cells to regenerate cartilage in 30–45 minutes. Clinical trials show IKDC score improvements averaging 32.4 points — nearly double the threshold for clinically significant change — when administered in early focal cartilage damage where joint space remains.An injectable collagen scaffold called ChondroFiller recruits the patient's own repair cells to regenerate cartilage in 30–45 minutes. Clinical trials show IKDC score improvements averaging 32.4 points — nearly double the threshold for clinically significant change — when administered in early focal cartilage damage where joint space remains.
ChondroFiller vs hyaluronic acid for cartilage repairChondroFiller vs hyaluronic acid for cartilage repair
ChondroFiller repairs focal cartilage lesions by recruiting the patient's own cells; hyaluronic acid eases broad osteoarthritis by restoring synovial fluid. These injections treat fundamentally different conditions, and selecting the wrong one offers little clinical value.ChondroFiller repairs focal cartilage lesions by recruiting the patient's own cells; hyaluronic acid eases broad osteoarthritis by restoring synovial fluid. These injections treat fundamentally different conditions, and selecting the wrong one offers little clinical value.
ChondroFiller injection versus knee replacement for focal defectsChondroFiller injection versus knee replacement for focal defects
ChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.ChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.
Single-stage vs two-stage ACI for cartilage repairSingle-stage vs two-stage ACI for cartilage repair
Traditional two-stage ACI involves two general anaesthetics separated by a four-to-six-week cell culture period; STACI performs both stages in a single theatre session, requiring one general anaesthetic and eliminating the inter-stage gap.Traditional two-stage ACI involves two general anaesthetics separated by a four-to-six-week cell culture period; STACI performs both stages in a single theatre session, requiring one general anaesthetic and eliminating the inter-stage gap.
Who qualifies for ChondroFiller Liquid Cartilage injectionWho qualifies for ChondroFiller Liquid Cartilage injection
ChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.ChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.
What ChondroFiller's CE approval means for UK patientsWhat ChondroFiller's CE approval means for UK patients
ChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.ChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.
What the ChondroFiller evidence actually showsWhat the ChondroFiller evidence actually shows
ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.
How defect size and age decide OATS or OCAHow defect size and age decide OATS or OCA
Defect size determines whether focal cartilage repair uses autograft (OATS, harvested from the patient's own knee) or donor allograft (OCA): below 2 cm², autograft is viable; above 4 cm², only allograft remains before arthroplasty.Defect size determines whether focal cartilage repair uses autograft (OATS, harvested from the patient's own knee) or donor allograft (OCA): below 2 cm², autograft is viable; above 4 cm², only allograft remains before arthroplasty.
ChondroFiller and Arthrosamid serve different knee conditionsChondroFiller and Arthrosamid serve different knee conditions
ChondroFiller recruits progenitor cells to rebuild focal cartilage defects, whilst Arthrosamid provides permanent cushioning for diffuse osteoarthritis by integrating into the joint capsule; the choice between them follows from what MRI reveals about the damage pattern, not from symptom severity.ChondroFiller recruits progenitor cells to rebuild focal cartilage defects, whilst Arthrosamid provides permanent cushioning for diffuse osteoarthritis by integrating into the joint capsule; the choice between them follows from what MRI reveals about the damage pattern, not from symptom severity.
Who qualifies for a ChondroFiller injectionWho qualifies for a ChondroFiller injection
ChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.ChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.
How long ChondroFiller results lastHow long ChondroFiller results last
ChondroFiller's collagen scaffold biodegrades within 6–24 months, yet provides lasting clinical benefit by recruiting the patient's own cells to form repair tissue; 70–85% of well-selected patients maintain meaningful symptom relief at three to five years.ChondroFiller's collagen scaffold biodegrades within 6–24 months, yet provides lasting clinical benefit by recruiting the patient's own cells to form repair tissue; 70–85% of well-selected patients maintain meaningful symptom relief at three to five years.
154 results found in 51ms